Cardio Care Live

CME Presentations

PCSK9 Inhibitors and CV Risk Reduction


Presentations

  • CME
    1.0

    The Emerging Role of PCSK9 Inhibitors and CV Risk Reduction

    Speakers:Michael J. Blaha, MD, MPH, Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine
    Michael Miller, MD, FACC, FAHA, Professor of Cardiovascular Medicine, Epidemiology & Public Health

    Duration: 60 minutes

    Presented on: April 11, 2017

  • CME
    1.0

    CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their Implications

    Speakers:James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, Lipidology & Cardiovascular Disease Prevention, Clinical Assistant Professor of Medicine
    Marc S. Sabatine, MD, MPH, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine

    Duration: 60 minutes

    Presented on: May 23, 2017


Speakers

  • Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine

    Michael J. Blaha, MD, MPH, is director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, Maryland, and assistant professor of medicine at the Johns Hopkins Bloomberg School of Public Health. A practicing preventive noninvasive cardiologist, his work includes improving cardiovascular risk prediction through novel methods of early detection of atherosclerosis, including the use of cardiac computed tomography Dr Blaha is an associate editor for the journal Atherosclerosis, has published over 250 original papers, and two books on the metabolic syndrome. He is a founding member of The FIT Project, a principal investigator of the Coronary Artery Calcium Consortium, and co-director of the mobile health mActive Program at Johns Hopkins.
  • Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Professor of Cardiovascular Medicine, Epidemiology & Public Health

    Michael Miller, MD, FACC, FAHA, is professor of medicine at the University of Maryland School of Medicine in Baltimore and director of the Center for Preventive Cardiology for the University of Maryland Medical System. Dr Miller’s main research interests are disorders of lipid and lipoprotein metabolism; molecular studies of HDL cholesterol, triglycerides, and the postprandial response to dietary fat; nontraditional coronary risk factors; and clinical trials to reduce atherosclerosis. He serves on the Leadership Council of the American Heart Association (AHA), is a member of the AHA Nutrition and Lifestyle Committee, is past president of the American Society of Preventive Cardiology, and has published more than 250 scientific papers in leading medical journals such as JACC and JAMA.
  • James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    Lipidology & Cardiovascular Disease Prevention, Clinical Assistant Professor of Medicine

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, is a clinical assistant professor of medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease, and director of the Bellevue Hospital Lipid Clinic. Dr Underberg holds joint appointments in the Divisions of General Internal Medicine and Endocrinology at NYU. His clinical interests focus on the management of patients with lipids and lipoprotein disorders, and cardiovascular disease prevention. He maintains an active clinical research program in these areas, and has authored numerous articles and book chapters in the field of clinical lipidology. He is a diplomate of the American Board of Clinical Lipidology, and president-elect, board member and fellow of the National Lipid Association.
  • Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine

    Marc S. Sabatine, MD, MPH, is chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital, and a professor of medicine at Harvard Medical School in Boston, Massachusetts. As chairman of the TIMI Study Group, Dr Sabatine leads an academic research organization whose mission is to advance the knowledge and care of patients suffering from cardiovascular disease and its risk factors. He has led several large-scale, international, randomized controlled trials of novel antithrombotic, lipid-lowering and other pharmacotherapies, has a long-standing interest in pharmacogenetics, and has made seminal observations on the ability to use genetics for personalized medicine.

CME Information

 
ACTIVITY ACCREDITATION INFORMATION
ACTIVITY TITLE CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their ImplicationsACTIVITY FORMAT Internet Enduring Material FEE: There is no fee for this activity.   

TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management and CV disease risk reduction.

TYPE OF ACTIVITY Knowledge

EDUCATIONAL OBJECTIVES At the conclusion of this activity, all participants should be able to:

  • Identify the need for effective therapies for patients with familial hypercholesterolemia
  • Assess the efficacy and safety data for recent trials that examined the cardiovascular impact of PCSK9 inhibitors
  • Evaluate patient groups in which treatment beyond statins may be needed to decrease lipid-related CV risk
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

CRITERIA FOR SUCCESS To participate in the activity, go to http://www.cardiocarelive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the posttest. If you have questions about this CME/CE activity, please contact the NLA at cme@lipid.org. Please claim credit by November 23, 2017. For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

COMMERCIAL SUPPORT This activity is supported by an educational grant from Amgen.

CREDIT DESIGNATION

Credit provided by the National Lipid Association

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and PlatformQ Health Education, LLC. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement The National Lipid Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Pharmacists The National Lipid Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Universal Activity Number 0624-0000-17-026-L01-P (Knowledge) The National Lipid Association designates this continuing education activity for 1.00 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education

Nursing This educational activity for 1 contact hour is provided by The National Lipid Association. The National Lipid Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

FACULTY

PROGRAM CHAIR

Michael J. Blaha, MD, MPH Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine Johns Hopkins University

FEATURED FACULTY

Marc S. Sabatine, MD, MPH Chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group; Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School & NYU Center for CV Prevention; Director, Bellevue Hospital Lipid Clinic; President-Elect, National Lipid Association
FACULTY/PLANNER/STAFF FINANCIAL DISCLOSURES
FACULTY/PLANNER FINANCIAL DISCLOSURES
Name Relationship Company
Blaha, Michael Advisory Board Contracted Research Consultant Amgen, MedImmune, Novartis, Sanofi/Regeneron Aetna Foundation, Amgen Ferring, Siemens
Sabatine, Marc Contracted Research Consultant Amgen, AstraZeneca, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen Research Development, MedImmune, Merck & Co., Inc., Novartis, Pfizer, Poxel, Takeda Amgen, CVS Caremark, Esperion, Intarcia, Ionis, MedImmune, Merck & Co., Inc.
Underberg, James Advisory Board Contracted Research Consultant Speakers Bureau Akcea, Alexion, Amgen, Invitae, Regeneron, Sanofi Aegerion, Sanofi Amarin, Amgen Alexion, Amarin, Amgen, Regeneron, Sanofi, True Health Diagnostics
STAFF DISCLOSURES
PlatformQ Health Education, LLC N/A Nothing to Disclose
NLA N/A Nothing to Disclose
NLA CME REVIEWERS
Sean D. Stewart, PharmD N/A Nothing to Disclose

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

CONTACT INFORMATION

Accreditation Support: Please contact the National Lipid Association at cme@lipid.org.

Technical Support: For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.

 
ACTIVITY ACCREDITATION INFORMATION
ACTIVITY TITLE The Emerging Role of PCSK9 Inhibitors and CV Risk Reduction ACTIVITY TYPE Internet Enduring Material ACTIVITY FEE: There is no fee for this activity.   

TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management and CV disease risk reduction.

TYPE OF ACTIVITY Knowledge

EDUCATIONAL OBJECTIVES At the conclusion of this activity, all participants should be able to:

  • Identify the need for effective therapies for patients with familial hypercholesterolemia
  • Assess the efficacy and safety data for recent trials that examined the cardiovascular impact of PCSK9 inhibitors
  • Evaluate patient groups in which treatment beyond statins may be needed to decrease lipid-related CV risk
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

CRITERIA FOR SUCCESS To participate in the activity, go to http://www.cardiocarelive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the posttest. If you have questions about this CME/CE activity, please contact the NLA at cme@lipid.org. Please claim credit by October 11, 2017.

COMMERCIAL SUPPORT This activity is supported by an educational grant from Amgen.

CREDIT DESIGNATION

Credit provided by the National Lipid Association

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and PlatformQ Health Education, LLC. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement The National Lipid Association designates this enduring internet activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

FACULTY

PROGRAM CHAIR Michael J. Blaha, MD, MPH Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine Johns Hopkins University

FEATURED FACULTY Michael J. Blaha, MD, MPH Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine Johns Hopkins University Michael Miller, MD, FACC, FAHA Professor of Cardiovascular Medicine, Epidemiology & Public Health University of Maryland School of Medicine

FACULTY/PLANNER/STAFF FINANCIAL DISCLOSURES
FACULTY/PLANNER FINANCIAL DISCLOSURES
Name Relationship Company
Blaha, Michael Advisory Board Contracted Research Consultant Amgen, MedImmune, Novartis, Sanofi/Regeneron Aetna Foundation, Amgen Ferring, Siemens
Miller, Michael Consultant Amgen, Pfizer
STAFF DISCLOSURES
PlatformQ Health Education, LLC N/A Nothing to Disclose
NLA N/A Nothing to Disclose
NLA CME REVIEWERS
Suzana D. Zamecnik, NP N/A Nothing to Disclose

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.

ESTIMATED TIME TO COMPLETE This activity consists of one session, which should take approximately 1 hour to complete.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

CONTACT INFORMATION Accreditation Support: Please contact the National Lipid Association at cme@lipid.org.

Technical Support: For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.